Investor Relations

Investor Relations

News

Month Year

Month Year

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 29, 2023
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

August 14, 2023
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

June 28, 2023
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

June 26, 2023
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

June 21, 2023
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

June 05, 2023
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

June 02, 2023
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 24, 2023
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

May 11, 2023
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

April 26, 2023